Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $92 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• AXT appoints Tracy Liu to its board of directors